Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript

Eur J Haematol. 2014 Mar;92(3):263-7. doi: 10.1111/ejh.12234. Epub 2013 Nov 28.

Abstract

In addition to BCR, various rare fusion partners for the ABL1 gene have been reported in leukemia. We have identified the fusion gene SNX2-ABL1 in a pediatric case of acute lymphoblastic leukemia (ALL), which has only once previously been reported in an adult patient. Cytogenetic analysis detected this fusion gene arising from a t(5;9)(q22;q34) translocation. ALL cells carrying a SNX2-ABL1 fusion exhibited a BCR-ABL1+ ALL-like gene expression profile. The patient poorly responded to dasatinib but partially responded to imatinib. Treatment using tyrosine kinase inhibitors requires further investigation to optimize the genotype-based treatment stratification for patients with SNX2-ABL1 fusion.

Keywords: SNX2-ABL1; dasatinib; imatinib; precursor B-cell acute lymphoblastic leukemia; tyrosine kinase inhibitors.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Chromosomes / ultrastructure
  • Gene Expression Profiling
  • Gene Expression Regulation, Leukemic
  • Humans
  • Male
  • Oncogene Proteins, Fusion / genetics
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor Cells, B-Lymphoid / cytology
  • Protein Conformation
  • Protein Kinase Inhibitors / chemistry*
  • Proto-Oncogene Proteins c-abl / genetics*
  • Sequence Analysis, DNA
  • Sorting Nexins / genetics*
  • Translocation, Genetic
  • Treatment Outcome

Substances

  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • SNX2 protein, human
  • Sorting Nexins
  • Proto-Oncogene Proteins c-abl